Do menopause-related endocrine changes reduce free androgen signaling and anabolic response?

During the menopausal transition, systemic endocrine shifts alter steroidogenesis and nutrient pathways, directly impacting musculoskeletal health.

Hormonal interactions and SHBG dynamics

• Ovarian Decline and Precursors: The menopausal transition reduces overall androgenic precursor pools. Specifically, low DHEA sulfate (DHEA-S) levels restrict the local, peripheral conversion of precursors into active intracellular androgens within target tissues.
• SHBG and Estrone Elevation: Elevated estrone, the predominant circulating estrogen post-menopause, directly upregulates hepatic synthesis of sex hormone-binding globulin (SHBG) via increased mRNA expression. High circulating SHBG binds testosterone with high affinity, actively lowering the free, bioavailable fraction.

Micronutrient modulation and anabolic response

• Receptor and Synthesis Impairment: Zinc deficiency directly impairs systemic testosterone synthesis. Furthermore, the vitamin D receptor (VDR) is a zinc-binding nuclear receptor that interacts with androgen receptor (AR) pathways; dual deficiency of zinc and vitamin D impairs receptor-level signaling.
• Anabolic Decline: Attenuated free androgen signaling downregulates muscle protein synthesis pathways. In postmenopausal cohorts, reduced bioavailable testosterone and elevated SHBG are strongly associated with diminished lean muscle mass and an increased risk of sarcopenia.

Bottom line

• While the convergence of ovarian decline, low DHEA-S, elevated estrone, and zinc/vitamin D deficiencies reduces free androgen signaling to impair anabolic responses, the premise that high SHBG opposes this decline is incorrect. High SHBG actively drives the reduction in bioavailable androgens, accelerating lean tissue loss.